Decreased CXCL5 secretion by CKD + pravastatin BMCs compared with DMEM-treated CKD BMCs was confirmed by enzyme-linked immunosorbent assay (60 ± 12 vs. 98 ± 31 pg/ml; P = 0.0045). The gene discussed is CXCL5; the disease is chronic kidney disease.